St. Gely du Fesc, France

Jean-Charles Molimard


Average Co-Inventor Count = 4.7

ph-index = 10

Forward Citations = 228(Granted Patents)


Location History:

  • Saint Gely Du Gesf, FR (1994 - 1995)
  • Saint-Gely-du-Fesc, FR (1995 - 1998)
  • St. Gely du Fesc, FR (1996 - 1999)
  • Gely du Fesc, FR (1996 - 2001)

Company Filing History:


Years Active: 1994-2001

Loading Chart...
18 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jean-Charles Molimard

Introduction

Jean-Charles Molimard is a prominent inventor based in St. Gely du Fesc, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with neurotensin receptors. With a total of 18 patents to his name, Molimard's work has had a considerable impact on medical research and drug development.

Latest Patents

Among his latest patents is the invention of substituted 1-phenyl-3-pyrazolecarboxamides, which are active on neurotensin receptors. This invention relates to compounds that exhibit a strong affinity for neurotensin receptors, potentially leading to new therapeutic applications. The detailed formula and preparation methods for these compounds are outlined in his patent documentation.

Career Highlights

Throughout his career, Jean-Charles Molimard has worked with notable companies in the pharmaceutical industry, including Sanofi and Elf Sanofi. His expertise in medicinal chemistry and pharmacology has allowed him to contribute to various innovative projects and research initiatives.

Collaborations

Molimard has collaborated with esteemed colleagues such as Robert Boigegrain and Danielle Gully. These partnerships have fostered a collaborative environment that has enhanced the quality and scope of his research.

Conclusion

Jean-Charles Molimard's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a key figure in advancing medical science. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…